| Nanoparticle-induced complement activation: implications for cancer nanomedicine NM La-Beck, MR Islam, MM Markiewski Frontiers in immunology 11, 603039, 2021 | 56 | 2021 |
| Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a … MR Islam, J Patel, PI Back, H Shmeeda, K Adamsky, H Yang, C Alvarez, ... Nanotheranostics 6 (4), 451, 2022 | 15 | 2022 |
| Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model MR Islam, J Patel, PI Back, H Shmeeda, RR Kallem, C Shudde, ... Biomolecules 13 (9), 1309, 2023 | 7 | 2023 |
| Immune Implications of Cholesterol-Containing Lipid Nanoparticles PI Back, M Yu, S Modaresahmadi, S Hajimirzaei, Q Zhang, MR Islam, ... ACS nano 18 (42), 28480-28501, 2024 | 1 | 2024 |
| Targeting immune checkpoint pathways in melanoma: triumphs and challenges PI Back, K Rascon, MR Islam, C Selby, NM La-Beck Future Drug Discovery 5 (1), FDD81, 2023 | 1 | 2023 |
| Impact of liposomal drug delivery and alendronate co-encapsulation on the immune modulatory effects of doxorubicin in the tumor microenvironment MR Islam, J Patel, PI Back, H Shmeeda, K Adamsky, H Yang, C Alvarez, ... CANCER IMMUNOLOGY RESEARCH 10 (12), 2022 | | 2022 |
| Abstract A42: Impact of liposomal drug delivery and alendronate co-encapsulation on the immune modulatory effects of doxorubicin in the tumor microenvironment MR Islam, J Patel, PI Back, H Shmeeda, K Adamsky, H Yang, C Alvarez, ... Cancer Immunology Research 10 (12_Supplement), A42-A42, 2022 | | 2022 |
